scholarly journals A clinician’s guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer

2020 ◽  
Vol 146 (8) ◽  
pp. 2067-2075
Author(s):  
Kevin M. Veen ◽  
Isabel B. de Angst ◽  
Mostafa M. Mokhles ◽  
Hans M. Westgeest ◽  
Malou Kuppen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prediction Model ◽  
Real World ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
World Data ◽  
Castration Resistant

A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 180-180 ◽  
Author(s):  
A. Oliver Sartor ◽  
Sreevalsa Appukkuttan ◽  
Ronald E. Aubert ◽  
Jeffrey Weiss ◽  
Joy Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Pilot Trial ◽  
Clinical Trial Data ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
Data Set ◽  
World Data ◽  
Castration Resistant ◽  
Radium 223

180 Background: Radium-223 (RA-223) is the first FDA approved targeted alpha therapy that significantly improves overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) with symptomatic bone metastases. There is limited real world data describing RA-223 current use. Methods: A retrospective patient chart review was done of men who received at least 1 cycle of Ra-223 for mCRPC in 10 centers throughout the US (4 academic, 6 private practices). All pts had a minimum follow-up of 4 months, or placed in hospice or death. Descriptive analyses for clinical characteristics and treatment outcomes were performed. Results: Among the 200 pts (mean age-73.6 years, mean Charlson comorbidity index-6.9) RA-223 was initiated on average 1.6 years from mCRPC diagnosis (first line use (1L)=38.5%, 2L=31.5% and ≥3L=30%). 78% completed 5-6 cycles of RA-223 with mean therapy duration of 4.2 months. Among all pts, 43% received RA-223 as monotherapy (no overlap with other mCRPC therapies) while 57% had combination therapy with either abiraterone or enzalutamide. Median OS following RA-223 initiation was 21.2 months (95% CI 19.6- 29.2). Table provides the RA-223 utilization by type of clinical practice. Conclusions: Utilization of RA-223 in this real world data set was distinct from clinical trial data. Most patients received RA-223 in combination with abiraterone or enzalutamide, therapies that were unavailable when the pilot trial was conducted. Median survival was 21.2 months. Real world use of RA-223 has evolved as newer agents have become FDA approved in bone-metastatic CRPC. Academic and community patterns of practice were more similar than distinct. [Table: see text]

Enzalutamide in metastatic castration-resistant prostate cancer after chemotherapy: Real-world data

2019 ◽  
Vol 18 (11) ◽  
pp. e3472
Author(s):  
L. Castro Oliveira ◽  
F. Ferreira Pereira ◽  
A. Rosinha ◽  
F. Carneiro ◽  
C. Faustino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
World Data ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document